Pharming Group N.V. announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025, marking a strategic leadership enhancement as the rare disease-focused biopharmaceutical company continues its growth trajectory. The appointment follows strong first half 2025 financial results and represents an important step in strengthening the company's financial leadership capabilities.
Extensive Life Sciences Leadership Experience
Lynard brings over 20 years of global leadership experience in the life sciences industry, with a track record of driving financial and operational transformation across complex, multinational organizations. Most recently, he served as CFO of Schoeller Allibert and Zentiva, a European pharmaceutical company, and previously held the CFO position at Affidea.
His most notable tenure was at Gilead Sciences, where he served as Senior Vice President and CFO for Global Commercial Operations, R&D and Manufacturing. During his five-year tenure at the leading US-based biopharmaceutical company, Lynard worked closely with top leadership on capital allocation and pipeline funding strategies, contributing to a tripling of the business following the Pharmasset acquisition as the company expanded into broader therapeutic areas and new geographies.
Earlier in his career, Lynard held finance leadership positions at Medtronic, Coloplast and Superfos. As a former Big Five public accountant with Arthur Andersen, he brings a solid foundation in compliance and internal controls, with a forward-looking approach to leveraging systems and data for business optimization.
Strategic Vision for Rare Disease Focus
Fabrice Chouraqui, Chief Executive Officer of Pharming, emphasized the strategic importance of the appointment: "We are delighted to welcome Kenneth to Pharming at a pivotal stage in our growth. Kenneth brings broad finance leadership capabilities from both established industry leaders and dynamic growth-stage companies, and operational experience in both the U.S. and EU. His strong value creation mindset, shaped by experience with companies backed by leading private equity firms, will be extremely valuable as we continue to advance our vision of building a leading global rare disease company."
Lynard expressed his commitment to the company's mission, stating: "I'm excited to join Pharming at such a pivotal moment in its evolution. The company's strong growth momentum, combined with upcoming commercial and pipeline catalysts, reflects a solid foundation for long-term success. As the new Chief Financial Officer, I look forward to strengthening the foundations to enable continued operational efficiency and support sustainable value creation. What truly inspires me, however, is Pharming's deep commitment to patients, especially those with few or no treatment options, and often unaware they are living with a rare disease."
Educational Background and Global Perspective
Lynard is a Danish citizen who holds a Master of Science in Business Economics and Auditing from Copenhagen Business School, Denmark, and an executive MBA from the International Institute for Management Development (IMD) in Lausanne, Switzerland. This international educational background complements his operational experience across both U.S. and European markets.
Company Profile and Market Reach
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is commercializing and developing a portfolio of innovative medicines, including small molecules and biologics. Headquartered in Leiden, the Netherlands, Pharming has employees around the globe who serve patients in over 30 markets across North America, Europe, the Middle East, Africa, and Asia-Pacific.
